CEREP Stock Euronext Paris
Equities
FR0004042232
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
2023 | Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
2022 | Eurofins-Cerep SA Reports Earnings Results for the Half Year Ended June 30, 2022 | CI |
Sales 2021 | 41.63M 44.53M 60.99M | Sales 2022 | 47.65M 50.97M 69.8M | Capitalization | 112M 120M 164M |
---|---|---|---|---|---|
Net income 2021 | 9M 9.63M 13.18M | Net income 2022 | 11M 11.77M 16.11M | EV / Sales 2021 | 2.05 x |
Net cash position 2021 | 1.28M 1.37M 1.88M | Net cash position 2022 | 12.81M 13.7M 18.76M | EV / Sales 2022 | 2.08 x |
P/E ratio 2021 * |
-
| P/E ratio 2022 |
-
| Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 4.22% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 18-04-18 | |
Damien Séroux
CHM | Chairman | - | 14-10-12 |
Members of the board | Title | Age | Since |
---|---|---|---|
Damien Séroux
CHM | Chairman | - | 14-10-12 |
Director/Board Member | 68 | 15-06-09 | |
Chief Executive Officer | - | 18-04-18 |
1st Jan change | Capi. | |
---|---|---|
+1.77% | 42.86B | |
+47.70% | 41.36B | |
+12.24% | 42.74B | |
-8.83% | 27.68B | |
+7.44% | 25.15B | |
-23.01% | 18.63B | |
+30.56% | 12.37B | |
-1.82% | 11.92B | |
+8.35% | 11.21B |